The goal of this clinical trial is to investigate the use of pentoxifylline (PTX) as a novel pharmacologic agent for patients with Crohn's disease (CD). CD is a chronic, relapsing inflammatory bowel disease (IBD) that cannot be cured with either surgery or currently available medical therapies. CD is characterized histologically by transmural infiltration of the intestine with T-cells, B-cells, and macrophages, and clinically by abdominal pain, diarrhea, and weight loss. Although the etiology of CD remains elusive, the host systemic and mucosal immune system are central to the disease pathogenesis. The factors responsible for the initiation and perpetuation of the damaging immune responses are unknown, but increasing evidence implicates cytokines, soluble mediators of inflammation, in this process. Pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-alpha) and interleukin 1 beta (IL-1beta), are central to the modulation of mucosal inflammation. The central hypothesis of this proposal is that PTX will improve clinical symptoms of patients with CD by selectively decreasing TNF-alpha levels in the intestinal mucosa. This hypothesis will be tested by the following specific aims:
Aim 1 : Investigate the efficacy and safety of PTX in the treatment of CD.
Aim 2 : Measure mucosal production of TNF-alpha before and after treatment with PTX.
|Bustos, Martha L; Caritis, Steve N; Jablonski, Kathleen A et al. (2017) The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth. Am J Obstet Gynecol 217:369.e1-369.e9|
|Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445|
|James, Jennifer; Munson, David; DeMauro, Sara B et al. (2017) Outcomes of Preterm Infants following Discussions about Withdrawal or Withholding of Life Support. J Pediatr 190:118-123.e4|
|O'Toole, John F; Bruggeman, Leslie A; Madhavan, Sethu et al. (2017) The Cell Biology of APOL1. Semin Nephrol 37:538-545|
|Grams, Morgan E; Yang, Wei; Rebholz, Casey M et al. (2017) Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 70:337-346|
|Tita, Alan T N; Lai, Yinglei; Landon, Mark B et al. (2017) Predictive Characteristics of Elevated 1-Hour Glucose Challenge Test Results for Gestational Diabetes. Am J Perinatol 34:1464-1469|
|Chen, Teresa K; Appel, Lawrence J; Grams, Morgan E et al. (2017) APOL1 Risk Variants and Cardiovascular Disease: Results From the AASK (African American Study of Kidney Disease and Hypertension). Arterioscler Thromb Vasc Biol 37:1765-1769|
|Denson, Lee A; McDonald, Scott A; Das, Abhik et al. (2017) Early Elevation in Interleukin-6 is Associated with Reduced Growth in Extremely Low Birth Weight Infants. Am J Perinatol 34:240-247|
|DiMarco, Anthony F; Geertman, Robert T; Tabbaa, Kutaiba et al. (2017) Economic Consequences of an Implanted Neuroprosthesis in Subjects with Spinal Cord Injury for Restoration of an Effective Cough. Top Spinal Cord Inj Rehabil 23:271-278|
|Chen, Teresa K; Tin, Adrienne; Peralta, Carmen A et al. (2017) APOL1 Risk Variants, Incident Proteinuria, and Subsequent eGFR Decline in Blacks with Hypertension-Attributed CKD. Clin J Am Soc Nephrol 12:1771-1777|
Showing the most recent 10 out of 742 publications